Kanada - angol - Health Canada

sivem pharmaceuticals ulc - lorazepam - tablet - 0.5mg - lorazepam 0.5mg - benzodiazepines

Kanada - angol - Health Canada

sivem pharmaceuticals ulc - lorazepam - tablet - 1mg - lorazepam 1mg - benzodiazepines

Kanada - angol - Health Canada

sivem pharmaceuticals ulc - lorazepam - tablet - 2mg - lorazepam 2mg - benzodiazepines

Kanada - angol - Health Canada

sandoz canada incorporated - lorazepam - solution - 2mg - lorazepam 2mg - benzodiazepines

Egyesült Államok - angol - NLM (National Library of Medicine)

sagent pharmaceuticals - pentobarbital sodium (unii: njj0475n0s) (pentobarbital - unii:i4744080ir) - pentobarbital sodium 50 mg in 1 ml - - sedatives. - hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks. (see "clinical pharmacology" section.) - preanesthetics. - anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. barbiturates are contraindicated in patients with known barbiturate sensitivity. barbiturates are also contraindicated in patients with a history of manifest or latent porphyria. pentobarbital sodium injection is subject to control by the federal controlled substances act under dea schedule ii. barbiturates may be habit forming. tolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. daily administration in excess of 400 milligrams (mg) of pentobarbital or secobar

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride, quantity: 22.2 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate; lactose; hyprolose; hypromellose; macrogol 8000; titanium dioxide - treatment of major depression and prevention of relapse of depressive symptoms. treatment of obsessive compulsive disorder (ocd) and prevention of relapse of ocd. treatment of panic disorder and prevention of relapse of panic disorder. treatment of social anxiety disorder / social phobia. treatment of generalised anxiety disorder. treatment of post-traumatic stress disorder.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride, quantity: 22.22 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; microcrystalline cellulose; mannitol; basic butylated methacrylate copolymer; titanium dioxide; purified talc; polyvinyl alcohol; sodium lauryl sulfate; glyceryl monostearate - treatment of major depression and for the prevention of relapse of depressive symptoms; treatment of obsessive compulsive disorder and for the prevention of relapse of ocd; treatment of panic disorder and for the prevention of relapse of panic disorder; treatment of social anxiety disorder/ social phobia; treatment of generalised anxiety disorder; and treatment of post-traumatic stress disorder

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - acebutolol hydrochloride - oral tablet - 400mg

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - acebutolol hydrochloride - oral tablet - 400mg

Egyesült Királyság - angol - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - acebutolol hydrochloride - oral tablet - 400mg